CA2116563C
(en)
*
|
1991-08-30 |
2001-07-03 |
Yoji Ito |
Dry gel pharmaceutical composition
|
US5605930A
(en)
*
|
1991-10-21 |
1997-02-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Compositions and methods for treating and preventing pathologies including cancer
|
CA2121435C
(en)
*
|
1993-04-16 |
2002-01-22 |
Sheila M. Ratnaraj |
Aqueous pharmaceutical suspension and process for preparation thereof
|
FR2713931B1
(fr)
*
|
1993-12-20 |
1996-04-05 |
Laurence Paris |
Nouvelles compositions pharmaceutiques liquides à base d'ibuprofène et leur procédé de préparation.
|
NZ272574A
(en)
*
|
1995-07-14 |
1999-02-25 |
Lilly Eli & Co Nz Ltd |
Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment
|
DK0839024T3
(da)
*
|
1995-07-14 |
2004-08-16 |
Elli Lilly & Co Nz Ltd |
Ionofore antibiotiske formuleringer
|
NZ280384A
(en)
|
1995-11-02 |
1997-01-29 |
Lilly Eli & Co Nz Ltd |
Animal feed supplement comprising a wettable powder composition of an ionophore antibiotic
|
AUPN862596A0
(en)
*
|
1996-03-12 |
1996-04-04 |
F.H. Faulding & Co. Limited |
Pharmaceutical compositions
|
AU717764B2
(en)
*
|
1996-05-02 |
2000-03-30 |
Taisho Pharmaceutical Co., Ltd. |
Suspension of sparingly water-soluble acidic drug
|
US5712310A
(en)
*
|
1996-06-14 |
1998-01-27 |
Alpharma Uspd, Inc. |
Suspension of substantially water-insoluble drugs and methods of their manufacture
|
US20110189348A1
(en)
*
|
1998-10-28 |
2011-08-04 |
San-Ei Gen F.F.I., Inc. |
Compositions containing sucralose and application thereof
|
WO2000024273A1
(fr)
*
|
1998-10-28 |
2000-05-04 |
San-Ei Gen F.F.I., Inc. |
Compositions contenant du sucralose, et applications correspondantes
|
USH2044H1
(en)
|
1998-11-02 |
2002-09-03 |
Mcneil-Ppc, Inc. |
Container with retaining member
|
BR0009557A
(pt)
|
1999-04-06 |
2002-05-28 |
Ethypharm Lab Prod Ethiques |
Suspensão farmacêutica para beber de ibuprofeno
|
US6211246B1
(en)
*
|
1999-06-10 |
2001-04-03 |
Mcneil-Ppc, Inc. |
Rapidly absorbed liquid compositions
|
US6726922B1
(en)
|
1999-06-28 |
2004-04-27 |
Minu, L.L.C. |
Process and composition for temporarily suppressing pain
|
US6737094B2
(en)
|
2000-05-31 |
2004-05-18 |
Pepsico, Inc. |
Low-staining orange food coloring composition
|
AU2001275784A1
(en)
*
|
2000-08-02 |
2002-02-13 |
Malope Company Limited |
Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormality
|
JP4204864B2
(ja)
*
|
2000-12-25 |
2009-01-07 |
ライオン株式会社 |
懸濁液の安定化方法及び安定化された懸濁液
|
PT1232746E
(pt)
*
|
2001-02-14 |
2006-11-30 |
Forte Iq B V |
Composição farmacêutica que compreende goma xantana
|
CA2440412A1
(en)
|
2001-03-05 |
2002-09-19 |
Ortho-Mcneil Pharmaceutical, Inc. |
Taste masked liquid pharmaceutical compositions
|
HUP0400856A3
(en)
*
|
2001-04-03 |
2012-09-28 |
Merck Sharp & Dohme |
Antifungal composition
|
NZ530889A
(en)
*
|
2001-07-31 |
2005-03-24 |
Wyeth Corp |
Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
|
US6770263B1
(en)
*
|
2001-10-01 |
2004-08-03 |
Naturewell, Incorporated |
Compositions and methods for the treatment of aches and pains
|
US20040132823A1
(en)
*
|
2001-11-02 |
2004-07-08 |
Leo Pavliv |
Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
|
ES2197781B1
(es)
*
|
2001-12-04 |
2005-02-16 |
Farmalider, S.A. |
Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
|
US6998480B2
(en)
|
2002-03-08 |
2006-02-14 |
Tate & Lyle Public Limited Company |
Process for improving sucralose purity and yield
|
US7049435B2
(en)
|
2002-03-08 |
2006-05-23 |
Tate & Lyle Public Limited Company |
Extractive methods for purifying sucralose
|
US7300670B2
(en)
|
2002-04-03 |
2007-11-27 |
Unilab Pharmatech, Ltd. |
Oral suspension formulation
|
US20040258716A1
(en)
*
|
2002-06-17 |
2004-12-23 |
Shen Gao |
Ibuprofen suspension
|
US20030232097A1
(en)
*
|
2002-06-17 |
2003-12-18 |
Strides Inc. |
Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
|
KR100509432B1
(ko)
*
|
2002-12-13 |
2005-08-22 |
주식회사 동구제약 |
S(+)-이부프로펜을 함유한 시럽제 조성물 및 그의 제조방법
|
US20040253311A1
(en)
*
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
CL2003002653A1
(es)
*
|
2002-12-18 |
2005-04-22 |
Wyeth Corp |
Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
|
US20040186180A1
(en)
*
|
2003-03-21 |
2004-09-23 |
Gelotte Cathy K. |
Non-steroidal anti-inflammatory drug dosing regimen
|
WO2005025622A1
(ja)
*
|
2003-09-12 |
2005-03-24 |
Ryukakusan Co. Ltd. |
苦みマスキング粒状ゼリー飲料
|
US20050069590A1
(en)
*
|
2003-09-30 |
2005-03-31 |
Buehler Gail K. |
Stable suspensions for medicinal dosages
|
US20050095299A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Wynn David W. |
Controlled release analgesic suspensions
|
US20050095300A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Wynn David W. |
Controlled release analgesic suspensions
|
US20060088593A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20060087051A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20070281022A1
(en)
*
|
2004-10-27 |
2007-12-06 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20060088586A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20070190133A1
(en)
*
|
2004-10-27 |
2007-08-16 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US8383159B2
(en)
*
|
2004-10-27 |
2013-02-26 |
Mcneil-Ppc, Inc. |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20060088587A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20060093631A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Buehler Gail K |
Dye-free pharmaceutical suspensions and related methods
|
US20060093629A1
(en)
|
2004-10-29 |
2006-05-04 |
Buehler Gail K |
Dye-free pharmaceutical suspensions and related methods
|
US20060093630A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Buehler Gail K |
Dye-free pharmaceutical suspensions and related methods
|
US20060094760A1
(en)
*
|
2004-11-04 |
2006-05-04 |
Fawzy Abdel A |
Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
|
US7611695B2
(en)
*
|
2004-11-15 |
2009-11-03 |
Ultradent Products, Inc. |
Flavored hemostatic and acid etching compositions
|
NZ555501A
(en)
|
2004-11-24 |
2010-01-29 |
Medpointe Healthcare Inc |
Compositions comprising azelastine and methods of use thereof
|
US8758816B2
(en)
*
|
2004-11-24 |
2014-06-24 |
Meda Pharmaceuticals Inc. |
Compositions comprising azelastine and methods of use thereof
|
US20070020330A1
(en)
|
2004-11-24 |
2007-01-25 |
Medpointe Healthcare Inc. |
Compositions comprising azelastine and methods of use thereof
|
EP1824493B1
(en)
*
|
2004-12-06 |
2008-08-13 |
Janssen Pharmaceutica N.V. |
Oral suspension comprising meloxicam
|
BRPI0709606B8
(pt)
|
2006-03-16 |
2021-05-25 |
Tris Pharma Inc |
suspensão líquida administrável oralmente com características de liberação modificada
|
GB2438287A
(en)
|
2006-05-19 |
2007-11-21 |
Norbrook Lab Ltd |
Stable aqueous suspension
|
US20080014275A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Buehler Gail K |
Pharmaceutical suspensions and related methods
|
CN101534795B
(zh)
|
2006-11-21 |
2013-04-03 |
麦克内尔-Ppc股份有限公司 |
改进释放的镇痛悬浮液
|
US8895061B2
(en)
*
|
2007-03-02 |
2014-11-25 |
Meda Pharmaceuticals Inc. |
Compositions comprising carisoprodol and methods of use thereof
|
CN101679844B
(zh)
*
|
2007-03-09 |
2014-06-18 |
赫尔克里士公司 |
用于油田的羟乙基纤维素的稳定硫代硫酸钠基流化聚合物悬浮液
|
US20080260837A1
(en)
*
|
2007-04-20 |
2008-10-23 |
Qpharma, L.L.C. |
Physically stable aqueous suspensions of active pharmaceuticals
|
US20080268025A1
(en)
*
|
2007-04-25 |
2008-10-30 |
Donald Spector |
Compositions Useful for Preventing Pain and Soreness Resulting from Exercise and Methods of Use
|
US9833510B2
(en)
*
|
2007-06-12 |
2017-12-05 |
Johnson & Johnson Consumer Inc. |
Modified release solid or semi-solid dosage forms
|
WO2009085959A1
(en)
|
2007-12-20 |
2009-07-09 |
Organic Recovery, Llc |
Methods and compositions for digestion of organic waste
|
CA2711211A1
(en)
*
|
2008-01-03 |
2009-07-09 |
Aft Pharmaceuticals Ltd. |
Oral pharmaceutical suspension comprising paracetamol and ibuprofen
|
AR070082A1
(es)
*
|
2008-01-04 |
2010-03-10 |
Tate & Lyle Technology Ltd |
Metodo para la produccion de sucralosa
|
CN101977664B
(zh)
*
|
2008-03-20 |
2014-02-26 |
塔特和莱利技术有限公司 |
从叔酰胺溶剂中去除酸
|
US8436157B2
(en)
*
|
2008-03-26 |
2013-05-07 |
Tate & Lyle Technology Limited |
Method for the production of sucralose
|
US8497367B2
(en)
*
|
2008-04-03 |
2013-07-30 |
Tate & Lyle Technology Limited |
Sucralose purification process
|
WO2009124113A1
(en)
*
|
2008-04-03 |
2009-10-08 |
Tate & Lyle Technology Ltd. |
Extraction of less polar impurities from sucralose containing aqueous feed streams
|
AR071134A1
(es)
*
|
2008-04-03 |
2010-05-26 |
Tate & Lyle Technology Ltd |
Cristalizacion de sucralosa a partir de chorros que contienen sucralosa
|
US20090299055A1
(en)
*
|
2008-04-03 |
2009-12-03 |
Tate & Lyle Technology Limited |
Purification of Sucralose Containing Feed Streams for Sucralose Crystallization
|
CN101981044B
(zh)
*
|
2008-04-03 |
2014-08-06 |
塔特和莱利技术有限公司 |
碳水化合物浓度对三氯半乳蔗糖萃取效率的影响
|
AR074052A1
(es)
|
2008-10-22 |
2010-12-22 |
Array Biopharma Inc |
Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
|
CA2755543A1
(en)
*
|
2009-03-13 |
2010-09-16 |
Nucitec S.A. De C.V. |
Compositions and methods for treatment and prevention of cardiovascular disease
|
GB2469158B
(en)
|
2009-03-31 |
2011-09-28 |
Peter J Seaberg |
Base-assisted formation of tin-sucrose adducts
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
GB2474311B
(en)
*
|
2009-10-12 |
2012-10-17 |
Tate & Lyle Technology Ltd |
Low temperature, single solvent process for the production of sucrose-6-ester
|
GB2474310B
(en)
|
2009-10-12 |
2012-02-29 |
Tate & Lyle Technology Ltd |
Process for the production of sucrose-6-ester
|
GB201110520D0
(en)
|
2011-05-10 |
2011-08-03 |
Tate & Lyle Technology Ltd |
Extraction of carboxylic acids with tin compounds
|
JP6532937B2
(ja)
|
2014-05-05 |
2019-06-19 |
カル セーフ ソイル, エルエルシー |
栄養豊富な組成物
|
JP6914834B2
(ja)
|
2014-11-16 |
2021-08-04 |
アレイ バイオファーマ インコーポレイテッド |
(S)−N−(5−((R)−2−(2,5−ジフルオロフェニル)−ピロリジン−1−イル)−ピラゾロ[1,5−a]ピリミジン−3−イル)−3−ヒドロキシピロリジン−1−カルボキサミド硫酸水素塩の結晶形
|
EP3061501A1
(en)
|
2015-02-27 |
2016-08-31 |
Rottapharm Ltd. |
Composition for the treatment of acne
|
EP3117825A1
(en)
|
2015-07-16 |
2017-01-18 |
Rottapharm S.p.A. |
Oral formulation comprising berberine and morus alba extract
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
AU2016344058A1
(en)
|
2015-10-26 |
2018-05-17 |
Array Biopharma Inc. |
Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
RU2751767C2
(ru)
|
2016-04-04 |
2021-07-16 |
Локсо Онколоджи, Инк. |
Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
|
KR102566858B1
(ko)
|
2016-05-18 |
2023-08-11 |
어레이 바이오파마 인크. |
(s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
US20200206352A1
(en)
*
|
2017-08-31 |
2020-07-02 |
Tohoku University |
Optimal osmotic range for a drug-containing solution suitable for lymphatic delivery
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
EP3700576A1
(en)
*
|
2017-10-26 |
2020-09-02 |
Array Biopharma Inc. |
Formulations of a macrocyclic trk kinase inhibitor
|
GB2585825B
(en)
*
|
2019-07-09 |
2023-03-22 |
Lexon Uk Holdings Ltd |
Suspending vehicle formulation
|
CN112516083B
(zh)
*
|
2020-12-15 |
2023-02-28 |
太阳升(亳州)生物医药科技有限公司 |
布洛芬混悬液及其制备方法
|
WO2024206425A1
(en)
|
2023-03-31 |
2024-10-03 |
Johnson & Johnson Consumer Inc. |
Therapeutic liquid compositions
|
WO2024206438A1
(en)
|
2023-03-31 |
2024-10-03 |
Johnson & Johnson Consumer Inc. |
Therapeutic suspension compositions
|